MASTERINVEST Kapitalanlage GmbH Purchases New Holdings in Edwards Lifesciences Corporation $EW

Key Points

• MASTERINVEST Kapitalanlage GmbH purchased 38,750 Edwards Lifesciences shares worth approximately $3.5 million in the second quarter. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences beat quarterly expectations, reporting $0.78 in EPS versus $0.74 expected and $1.74 billion in revenue, up 13.6% year over year. The company guided for third-quarter 2026 EPS of $0.71–$0.77.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $100.27 versus the stock’s reported price of $89.97.

MASTERINVEST Kapitalanlage GmbH purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 38,750 shares of the medical research company's stock, valued at approximately $3,505,000.

Several other hedge funds and other institutional investors have also bought and sold shares of EW. TrinityBridge Ltd bought a new position in Edwards Lifesciences in the 2nd quarter valued at $27,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $26,000. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences in the 1st quarter worth about $25,000. Kemnay Advisory Services Inc. purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $27,000. Finally, JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter valued at about $25,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,857 shares of company stock valued at $170,305 in the last three months. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Down 0.9%

EW opened at $89.97 on Friday. The company has a 50 day moving average of $89.48 and a 200 day moving average of $84.99. The company has a market cap of $51.81 billion, a PE ratio of 51.71, a price-to-earnings-growth ratio of 2.38 and a beta of 0.85. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the previous year, the business earned $0.67 EPS. Edwards Lifesciences's revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analysts Set New Price Targets

EW has been the subject of a number of research analyst reports. UBS Group began coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price objective for the company. Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. JPMorgan Chase & Co. increased their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Leerink Partners upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Finally, Citigroup lifted their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source